Takeda's Zasocitinib Beats Sotyktu With 35% Skin Clearance in Psoriasis Trial
Updated
Updated · BioPharma Dive · Jun 11
Takeda's Zasocitinib Beats Sotyktu With 35% Skin Clearance in Psoriasis Trial
3 articles · Updated · BioPharma Dive · Jun 11
Summary
35% of patients on Takeda’s zasocitinib reached PASI 100—complete skin clearance—after 16 weeks, about 2.5 times the rate seen with Bristol Myers Squibb’s Sotyktu.
Takeda said the oral TYK2 inhibitor was statistically superior on the trial’s main goal and all secondary endpoints, including PASI 90 and PASI 75, though it did not release full detailed data.
The result marks a second head-to-head win for zasocitinib after it previously beat Amgen’s Otezla, strengthening a drug Takeda bought from Nimbus Therapeutics for $4 billion upfront.
The win comes as Sotyktu has underwhelmed commercially—posting $291 million in 2025 sales—and as Bristol Myers scales back dermatology promotion in many markets.
Takeda still faces a crowded psoriasis market dominated by strong injectable biologics, while a closely watched inflammatory bowel disease readout later this year could further test zasocitinib’s broader potential.